慢性肾臟病市场按治疗方法、疾病阶段、最终用户、产品和患者类型划分－2025-2032年全球预测

预计到 2032 年，慢性肾臟病市场规模将达到 2,296.4 亿美元，复合年增长率为 6.71%。

这是一篇引人入胜且权威的概述，它将慢性肾臟病定位为一项紧迫的、多学科的临床和运营重点，需要协调一致的战略应对措施。

慢性肾臟病在临床照护、医疗系统韧性和人群健康管理等多个方面构成日益严峻的挑战。此疾病对诊断流程、长期治疗、透析基础设施和移植网络都提出了持续的需求，同时也常伴随糖尿病和心血管疾病等併发症。因此，从医疗设备製造商和药物研发者到医疗服务提供者和支付方，相关人员必须应对不断变化的临床标准、监管要求和患者照护模式。

深入分析重塑慢性肾臟病诊断、治疗和护理服务领域的关键临床、技术和经营模式变革。

慢性肾臟病治疗领域正经历着变革性的转变，这主要得益于技术创新、医疗服务模式的革新以及监管重点的不断调整。诊断准确性的提升使得早期发现和风险分层成为可能，而数位健康平台和远端监测则将临床监管的范围扩展到了传统的住院和门诊之外。同时，透析方式也不断多样化：血液透析机设备和腹膜透析週期计的改进，与支持个人化治疗方案的智慧耗材和监测设备相辅相成。

本文将实际检验近期关税政策将如何重塑2025年肾臟护理服务体系的供应链韧性、筹资策略与病患就医途径。

针对医疗技术和药品进口征收的特定关税正在对慢性肾臟病系统内的供应链、筹资策略和成本结构产生连锁反应。关税变化可能会改变进口透析设备、耗材和某些活性药物原料药与国产产品之间的相对竞争格局。因此，医疗机构和综合护理网络正在重新评估其采购合约、库存策略和供应商多元化，以确保依赖透析和移植的患者能够持续获得治疗。

基于详细细分市场的洞察，揭示了治疗方法类型、疾病阶段、医疗环境、产品分类和患者人口统计特征如何影响临床重点和商业策略。

要了解市场，需要对细分市场的各个维度进行细緻的观点，例如治疗方法类型、疾病阶段、最终用户、产品分类和患者群体，因为每个维度都会驱动不同的临床和商业性动态。基于治疗方法类型的诊疗路径涵盖范围广泛，从包括影像学和实验室检查在内的“诊断”，到包括血液透析和腹膜透析在内的“血液透析机”，再到抗高血压药物、促红细胞生成素刺激剂（例如Darbepoetinα、重组人促红血球生成素α）、铁剂、磷酸盐结合剂以及移植治疗及其术前和术后管理需求。每个治疗领域都有其独特的证据要求、监管考虑和采购週期。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 在医疗资源不足地区，越来越多地采用照护现场分子生物标记进行慢性肾臟病早期检测。
• 增加基因疗法的投资，以期逆转慢性肾臟病病患者的肾臟纤维化
• 推广家庭透析治疗技术（提供远端监测和个人化治疗调整）
• 穿戴式肾臟监测设备具备即时分析功能，能够追踪患者的水合状态和电解质平衡。
• 利用基因组数据开发精准医疗流程，对慢性肾臟病病患者的治疗路径进行分层。
• 将数位疗法与病人参与平台结合，以提高慢性肾臟病管理计画的治疗依从性

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章慢性肾臟病市场（依治疗方法）

• 诊断
  • 影像诊断
  • 测试诊断
• 透析
  • 血液透析机
  • 腹膜透析
• 製药
  • 抗高血压药物
  • 红血球生成素刺激剂
    • Darbepoetinα
    • 促红素α
  • 铁补充剂
  • 磷酸盐吸附剂
• 移植

第九章慢性肾臟病市场（依疾病阶段划分）

• 早期
• 末期肾功能衰竭
• 中度疾病
• 严重阶段

第十章 依最终用户分類的慢性肾臟病市场

• 门诊部
• 透析中心
• 居家医疗
• 医院

第十一章慢性肾臟病产品市场

• 消耗品
  • 导管和针头
  • 过滤器和透析器
• 装置
  • 血液透析机机
  • 腹膜透析循环装置
• 监测设备
  • 血液检测设备
  • 诊断影像系统

第十二章 依病患类型分類的慢性肾臟病市场

• 成人版
• 孩子们

第十三章慢性肾臟病市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章慢性肾臟病市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国慢性肾臟病市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Fresenius Medical Care AG & Co. KGaA
  • DaVita Inc.
  • Baxter International Inc.
  • B. Braun Melsungen AG
  • Nipro Corporation
  • Medtronic plc
  • Diaverum AB
  • NxStage Medical, Inc.
  • Terumo Corporation
  • Quanta Dialysis Technologies Ltd.

The Chronic Kidney Disease Market is projected to grow by USD 229.64 billion at a CAGR of 6.71% by 2032.

A compelling and authoritative overview positioning chronic kidney disease as an urgent multisectoral clinical and operational priority demanding coordinated strategic responses

Chronic kidney disease represents a multifaceted and growing challenge at the intersection of clinical care, health systems resilience, and population health management. The condition imposes sustained demands on diagnostic pathways, long-term therapeutics, dialysis infrastructure, and transplantation networks, while intersecting with comorbidities such as diabetes and cardiovascular disease. Consequently, stakeholders from device manufacturers and pharmaceutical developers to providers and payers must navigate evolving clinical standards, regulatory expectations, and shifting patient-care models.

Moving from isolated clinical encounters to integrated care delivery requires clarity about where the greatest friction points lie. Early detection through laboratory and imaging diagnostics can change trajectories, yet barriers to access and care coordination persist. In parallel, innovations in dialysis technology and transplant medicine are improving outcomes, though they compel systems-level planning for capacity and reimbursement. Taken together, these dynamics create both risk and opportunity: risk in the form of constrained access and rising costs for vulnerable populations, and opportunity in the form of innovation that can reduce morbidity and enable more efficient use of resources.

For decision-makers, the imperative is clear. Strategic investments that prioritize diagnostic accuracy, scalable dialysis modalities, pharmacologic optimization, and integrated care pathways will determine which organizations can deliver superior outcomes while managing total cost of care. This report frames that imperative by synthesizing clinical trends, operational pressures, and technological shifts to guide evidence-based decisions.

An incisive analysis of the major clinical, technological, and business model shifts reshaping chronic kidney disease care across diagnostics, therapeutics, and care delivery

The landscape of chronic kidney disease care is undergoing transformative shifts driven by technological innovation, care delivery redesign, and evolving regulatory attention. Advances in diagnostic precision are enabling earlier detection and risk stratification, while digital health platforms and remote monitoring are extending clinical oversight beyond traditional inpatient and clinic settings. At the same time, dialysis modalities are diversifying: improvements in hemodialysis hardware and peritoneal dialysis cyclers are complemented by smarter consumables and monitoring devices that support personalized treatment regimens.

These clinical and technological changes are also reshaping business models. Manufacturers are increasingly bundling devices with software services to create recurring revenue streams and improve patient adherence. Health systems are experimenting with home-based care and hybrid ambulatory models to reduce hospital dependence and enhance patient quality of life. Moreover, pharmaceutical management of anemia, mineral bone disorder, and blood pressure control is becoming more nuanced as novel agents and biosimilars enter clinical practice, necessitating updated formularies and clinical pathways.

As a result, organizations that integrate diagnostics, therapeutics, and digital monitoring into cohesive care pathways will be better positioned to improve outcomes and operational efficiency. Conversely, stakeholders that remain siloed risk falling behind as reimbursement and regulatory frameworks begin to favor integrated, value-oriented solutions. Understanding these shifts is essential for aligning investment, R&D, and clinical strategies with the future of kidney care.

A practical examination of how recent tariff policies reshape supply chain resilience, procurement strategies, and patient access across kidney care delivery systems in 2025

The introduction of targeted tariffs affecting medical technology and pharmaceutical imports has created ripple effects across supply chains, procurement strategies, and cost structures within the chronic kidney disease ecosystem. Tariff changes can alter the relative competitiveness of imported dialysis hardware, consumables, and certain active pharmaceutical ingredients versus domestically produced alternatives. In turn, providers and integrated delivery networks reassess procurement contracts, inventory strategies, and supplier diversification to ensure continuity of care for dialysis-dependent and transplant-reliant patients.

Operationally, higher import costs for capital equipment and consumables can accelerate conversations around asset utilization and lifecycle management. Facilities may extend equipment service lives, prioritize high-throughput modalities, or shift toward modular solutions that reduce dependence on high-cost imported components. Parallel to these operational responses, some manufacturers and contract manufacturers are exploring nearshoring and reconfigured manufacturing footprints to mitigate tariff exposure and shorten lead times. These moves can improve supply resilience but also require capital investment and regulatory alignment.

From a patient access perspective, tariffs can have indirect effects by affecting the cost base of care delivery and the timing of technology adoption. Payers and policy makers may respond through adjusted reimbursement policies, strategic subsidies, or procurement consortia designed to preserve access to essential therapies. Consequently, stakeholders should assess tariff-related scenarios proactively, incorporating supply chain risk modeling into procurement decisions, negotiating flexible purchase terms, and engaging with policymakers to ensure continuity of patient-centered services.

Detailed segmentation-driven insights revealing how therapy modalities, disease stages, care settings, product classes, and patient demographics determine clinical priorities and commercial strategies

Understanding the market requires a granular view across therapy types, disease stages, end users, product classes, and patient demographics, because each segmentation dimension drives distinct clinical and commercial dynamics. Based on therapy type, care pathways range from Diagnostics, which includes Imaging Diagnostics and Laboratory Diagnostics, to Dialysis, encompassing Hemodialysis and Peritoneal Dialysis, Pharmaceuticals comprising Antihypertensives, Erythropoietin Stimulating Agents such as Darbepoetin Alfa and Epoetin Alfa, Iron Supplements, and Phosphate Binders, and finally Transplantation with its own pre- and post-operative management needs. Each of these therapy domains generates unique evidence requirements, regulatory considerations, and procurement cycles.

Based on disease stage, the needs of patients differ markedly across Early Disease, Moderate Disease, Severe Disease, and End Stage Renal Disease, shaping diagnostic intensity, therapeutic regimens, and the urgency of access to dialysis or transplant services. Based on end user, care settings span Ambulatory Care Clinics, Dialysis Centers, Home Care environments, and Hospitals, each of which imposes distinct operational constraints, staffing models, and capital planning horizons. Based on product, clinical and purchasing decisions differentiate Consumables such as Catheters & Needles and Filters & Dialyzers, Equipment including Hemodialysis Machines and Peritoneal Dialysis Cyclers, and Monitoring Devices like Blood Testing Devices and Imaging Systems, thereby influencing vendor relationships and after-sales service models. Finally, based on patient type, Adult and Pediatric populations present different clinical protocols, device sizing requirements, and psychosocial support needs, which in turn inform specialized product development and care pathways.

Taken together, these segmentation lenses reveal that integrated strategies must be tailored: diagnostic innovations may yield greatest benefit in early stages, home-based dialysis growth hinges on device portability and consumable supply chains, pharmaceutical portfolio management requires alignment with stage-specific comorbidity profiles, and pediatric care demands dedicated attention to device design and family-centered delivery models. Consequently, stakeholders should design interventions with segmentation specificity, aligning R&D, regulatory planning, and commercial deployment to the clinical realities of each cohort and care setting.

A regionally nuanced analysis of how geopolitical, regulatory, and health system differences shape chronic kidney disease care priorities across major global regions

Regional dynamics exert powerful influence on how chronic kidney disease care is organized, financed, and delivered, and they shape strategic priorities for manufacturers, providers, and payers. In the Americas, health systems emphasize scale, centralized dialysis networks, and a growing interest in home-based modalities, alongside payer-driven efforts to control downstream costs through bundled payments and value-based care pilots. Regulatory pathways and reimbursement designs in this region influence adoption timelines for innovative devices and pharmaceuticals, and supply chain considerations often prioritize domestically compliant manufacturing or long-term distributor relationships.

In Europe, Middle East & Africa, a mosaic of regulatory regimes and funding mechanisms creates heterogenous adoption patterns. Western European systems tend to prioritize evidence-driven reimbursement and integrated care pathways, while parts of the Middle East and Africa face capacity constraints that elevate the importance of scalable, low-resource dialysis solutions and targeted training programs. Cross-border procurement, public-private partnerships, and donor-funded initiatives also play meaningful roles in expanding access.

In Asia-Pacific, rapid demographic change combined with a rising burden of chronic diseases has led to substantial investments in diagnostics, expanded dialysis capacity, and growing uptake of home therapies where feasible. Supply chain diversification is particularly salient in this region, with a mix of domestic manufacturing and international partnerships shaping product availability. Overall, regional strategies must balance clinical efficacy, affordability, and logistical feasibility, and organizations that tailor offerings to these geopolitical nuances will achieve stronger adoption and sustainable impact.

Actionable competitive intelligence highlighting how R&D investment, strategic partnerships, and service excellence are reshaping leadership across kidney care product and solution markets

Competitive dynamics in the chronic kidney disease arena are defined by a combination of technological capability, manufacturing scale, regulatory expertise, and strategic partnerships. Leading firms invest heavily in R&D for next-generation dialysis equipment, consumables that improve patient comfort and outcomes, and monitoring devices that enable remote patient management. Equally important are strategic alliances between device makers, pharmaceutical companies, and digital health providers that create integrated solutions spanning diagnostics to long-term management.

Additionally, contract manufacturing and supply chain partners are gaining prominence as companies seek to de-risk production and accelerate time to market. Firms that build robust post-market surveillance and service networks secure greater trust among providers, while those that offer data-enabled service models can demonstrate value through reduced hospitalizations and improved treatment adherence. M&A and equity partnerships continue to be tools for accelerating entry into new geographies or therapeutic niches, particularly where regulatory complexity or localized manufacturing capacity presents a barrier to rapid expansion.

Finally, a growing cohort of innovative entrants specializing in digital therapeutics, remote monitoring, and patient engagement is reshaping expectations around continuous care. Established companies that adopt open innovation models and invest in interoperability will be better positioned to capture long-term customer relationships and to deliver holistic care solutions that meet evolving payer and provider demands.

High-impact practical recommendations for executives to align clinical innovation, supply resilience, and commercial strategies to deliver better kidney care and sustained organizational advantage

Industry leaders must adopt a proactive stance that aligns clinical impact with operational resilience and commercial viability. First, strategic prioritization of integrated care pathways-linking diagnostics, therapeutics, monitoring, and dialysis services-will enable providers and manufacturers to demonstrate improved outcomes and cost efficiencies. Second, supply chain diversification and flexible procurement contracting will mitigate exposure to trade policy fluctuations and component shortages; nearshoring and multi-sourcing strategies should be evaluated alongside scenario-based inventory planning.

Third, investment in home-based care infrastructure and scalable remote monitoring platforms will expand access while improving patient experience, but success requires coordinated training, reimbursement engagement, and device suitability for diverse home environments. Fourth, pharmaceutical strategy should emphasize formulary alignment, real-world evidence generation, and collaboration with clinicians to optimize anemia and mineral bone disorder management across disease stages. Fifth, companies should build service-oriented business models that combine equipment, consumables, and data services to create recurring revenue and strengthen customer retention.

Finally, leaders must engage proactively with policymakers and payers to shape reimbursement frameworks that reward integrated, patient-centered care. By aligning clinical evidence generation with regulatory and payer requirements, organizations can accelerate adoption and secure sustainable pathways for scalable innovation. These combined actions will support resilient growth while improving outcomes for patients living with chronic kidney disease.

A transparent and methodical research approach combining primary stakeholder interviews, systematic secondary literature review, and scenario-based triangulation to support robust strategic conclusions

The research underpinning this analysis synthesizes primary qualitative insights and rigorous secondary data triangulation to ensure robust, actionable conclusions. Primary methods included structured interviews with clinicians, procurement leaders, dialysis center administrators, and industry executives to capture real-world operational constraints and adoption drivers. These stakeholder perspectives were complemented by an examination of regulatory communications, clinical guideline updates, and peer-reviewed literature to contextualize clinical trends and evidence requirements.

Secondary research encompassed systematic reviews of technical literature on dialysis technologies, pharmaceutical therapeutic classes, and diagnostic methodologies, combined with supplier and manufacturing landscape analysis to assess supply chain dependencies. Data triangulation techniques were applied to reconcile disparate sources and to surface consistent themes across geographies and care settings. Scenario analysis was used to explore the implications of supply chain disruptions and tariff changes, while sensitivity checks ensured that strategic recommendations remained robust under varying operational assumptions.

Throughout the process, emphasis was placed on transparency of assumptions and on documenting evidence hierarchies so that readers can trace conclusions to source material and stakeholder testimony. This methodology supports confident decision-making by blending frontline insights with documented clinical and operational evidence.

A concise and forward-looking synthesis underscoring the imperative for integrated, regionally tailored, and resilient strategies to improve outcomes across kidney care pathways

In closing, chronic kidney disease care is at an inflection point where advances in diagnostics, dialysis technology, pharmaceuticals, and digital monitoring can converge to produce meaningful gains in patient outcomes and system efficiency. However, realizing that potential will require integrated strategies that address segmentation-specific needs, regional nuances, and supply chain vulnerabilities. Stakeholders who proactively align clinical evidence generation with operational planning and payer engagement will be best positioned to translate innovation into scalable impact.

The path forward calls for cross-sector collaboration: manufacturers, providers, payers, and policymakers must work together to create reimbursement structures that reward integrated care, invest in workforce training for home-based and ambulatory models, and prioritize supply chain resilience to protect access to essential therapies. When these elements are aligned, the health system can deliver better quality of life for patients, optimize resource utilization, and foster sustainable innovation. This synthesis offers a strategic framework to guide next steps and to inform investments that will shape the future of kidney care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increasing adoption of point-of-care molecular biomarkers for early CKD detection in underserved populations
• 5.2. Growing investment in gene therapy approaches targeting renal fibrosis reversal in chronic kidney disease patients
• 5.3. Expansion of home-based dialysis technologies offering telemonitoring and personalized treatment adjustments
• 5.4. Emergence of wearable renal monitoring devices using real-time analytics to track patient hydration and electrolyte balance
• 5.5. Development of precision medicine pipelines utilizing genomics data to stratify CKD patient treatment pathways
• 5.6. Integration of digital therapeutics and patient engagement platforms to improve adherence in CKD management programs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Chronic Kidney Disease Market, by Therapy Type

• 8.1. Diagnostics
  • 8.1.1. Imaging Diagnostics
  • 8.1.2. Laboratory Diagnostics
• 8.2. Dialysis
  • 8.2.1. Hemodialysis
  • 8.2.2. Peritoneal Dialysis
• 8.3. Pharmaceuticals
  • 8.3.1. Antihypertensives
  • 8.3.2. Erythropoietin Stimulating Agents
    • 8.3.2.1. Darbepoetin Alfa
    • 8.3.2.2. Epoetin Alfa
  • 8.3.3. Iron Supplements
  • 8.3.4. Phosphate Binders
• 8.4. Transplantation

9. Chronic Kidney Disease Market, by Disease Stage

• 9.1. Early Disease
• 9.2. End Stage Renal Disease
• 9.3. Moderate Disease
• 9.4. Severe Disease

10. Chronic Kidney Disease Market, by End User

• 10.1. Ambulatory Care Clinic
• 10.2. Dialysis Center
• 10.3. Home Care
• 10.4. Hospital

11. Chronic Kidney Disease Market, by Product

• 11.1. Consumables
  • 11.1.1. Catheters & Needles
  • 11.1.2. Filters & Dialyzers
• 11.2. Equipment
  • 11.2.1. Hemodialysis Machine
  • 11.2.2. Peritoneal Dialysis Cycler
• 11.3. Monitoring Devices
  • 11.3.1. Blood Testing Devices
  • 11.3.2. Imaging Systems

12. Chronic Kidney Disease Market, by Patient Type

• 12.1. Adult
• 12.2. Pediatric

13. Chronic Kidney Disease Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Chronic Kidney Disease Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Chronic Kidney Disease Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Fresenius Medical Care AG & Co. KGaA
  • 16.3.2. DaVita Inc.
  • 16.3.3. Baxter International Inc.
  • 16.3.4. B. Braun Melsungen AG
  • 16.3.5. Nipro Corporation
  • 16.3.6. Medtronic plc
  • 16.3.7. Diaverum AB
  • 16.3.8. NxStage Medical, Inc.
  • 16.3.9. Terumo Corporation
  • 16.3.10. Quanta Dialysis Technologies Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CHRONIC KIDNEY DISEASE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DARBEPOETIN ALFA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EPOETIN ALFA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IRON SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EARLY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END STAGE RENAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MODERATE DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SEVERE DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY CARE CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CATHETERS & NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FILTERS & DIALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HEMODIALYSIS MACHINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS CYCLER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 229. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 230. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 231. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 232. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 233. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 234. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 235. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 236. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 237. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 238. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 239. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2024 (USD MILLION)
• TABLE 240. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2025-2032 (USD MILLION)
• TABLE 241. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
• TABLE 242. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
• TABLE 243. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 244. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 245. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 246. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 247. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 248. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 249. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
• TABLE 250. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
• TABLE 251. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
• TABLE 252. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
• TABLE 253. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 254. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 255. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 258. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 259. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 260. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 261. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 262. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 263. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 264. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 265. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2024 (USD MILLION)
• TABLE 266. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2025-2032 (USD MILLION)
• TABLE 267. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
• TABLE 268. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
• TABLE 269. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 272. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 273. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 274. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 275. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
• TABLE 276. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
• TABLE 277. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
• TABLE 278. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
• TABLE 279. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 280. NORTH AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 281. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 284. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 285. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
• TABLE 286. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
• TABLE 287. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2018-2024 (USD MILLION)
• TABLE 288. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, 2025-2032 (USD MILLION)
• TABLE 289. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
• TABLE 290. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
• TABLE 291. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2018-2024 (USD MILLION)
• TABLE 292. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULATING AGENTS, 2025-2032 (USD MILLION)
• TABLE 293. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
• TABLE 294. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
• TABLE 295. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 296. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 297. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 298. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 299. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 300. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 301. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
• TABLE 302. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
• TABLE 303. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
• TABLE 304. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
• TABLE 305. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 306. LATIN AMERICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 311. EURO